Diabetes market increasingly competitive

A number of pharmaceutical company setbacks in the last few months have made the drug market an increasingly less saturated field. The large, unpredictable hitches with a number of diabetes drugs have left a vacuum that drug developers are now fighting to fill.
Major hitches include heart risk warnings with Avandia and Actos, two blockbuster diabetes drug. Glaxo have reported a 38 per cent slump in Avandia sales. Furthermore, the oral insulin product Exubera has been pulled from the market by its manufacturer Pfizer Inc due to lacklustre sales.
Despite supply dropping off, the demand for new and established diabetes treatments continues to climb. Both the obesity and diabetes rates throughout the world are increasing.
Promising diabetes drugs on or near to market include Amylin’s Byetta and Merck’s Januvia.